Combined modality therapy for stage IIIA non-small cell carcinoma of the lung
Alan B. Weitberg(Roger Williams Medical Center), Connie Murray, Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Frank J. Cummings, Arvin S. Glicksman(Roger Williams Medical Center), Paul Calabresi, John Yashar, Julie Beitz, Marcia Browne, Jeffrey W. Clark(Massachusetts General Hospital)
Cited by 31
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k